XBI ETF holdings (NYSE) - Page 6 | MetaTrader

展开完整图表

概览所有持仓热图

主要持股 Market Value Shares Weight %

GERN Geron Corp 24.8 M 16.6 M 0.3%

Day One Biopharmaceuticals Inc 23.9 M 1.1 M 0.3%

PGEN Precigen Inc 23.2 M 6.0 M 0.3%

VIR Vir Biotechnology Inc 22.6 M 2.5 M 0.3%

K

KALV KalVista Pharmaceuticals Inc 21.7 M 1.1 M 0.3%

CTMX CytomX Therapeutics Inc 21.2 M 4.5 M 0.3%

ANNX Annexon Inc 21.2 M 3.8 M 0.3%

KURA Kura Oncology Inc 20.5 M 2.5 M 0.3%

INBX Inhibrx Biosciences Inc 19.9 M 296.6 K 0.3%

SLS SELLAS Life Sciences Group Inc 19.8 M 4.7 M 0.3%

JANX Janux Therapeutics Inc 19.8 M 1.4 M 0.3%

CMPX Compass Therapeutics Inc 19.5 M 3.7 M 0.3%

SVRA Savara Inc 19.4 M 3.6 M 0.3%

RIGL Rigel Pharmaceuticals Inc 19.2 M 708.8 K 0.3%

SANA Sana Biotechnology Inc 19.2 M 6.7 M 0.3%

CGEM Cullinan Therapeutics Inc 18.6 M 1.3 M 0.2%

SPRY ARS Pharmaceuticals Inc 17.8 M 2.2 M 0.2%

ZBIO Zenas Biopharma Inc 17.7 M 906.3 K 0.2%

XNCR Xencor Inc 17.2 M 1.4 M 0.2%

REPL Replimune Group Inc 16.8 M 2.2 M 0.2%

1
2
3
4
5
6
7
8

新闻

Gate 合约股票专区将上线 BOT（机器人策略封闭式基金）等 5 个永续合约交易

Oppenheimer维持Inovio制药"跑赢大盘"评级,关注加速审批途径

William Blair维持Compass Therapeutics增持评级,静待试验数据公布

Oppenheimer三月美股策略：动量策略正当时推荐苹果(AAPL.US)、美铝(AA.US)、贝克休斯(BKR.US)等个股

Citizens重申Ideaya Biosciences股票市场表现优于大盘评级

H.C. Wainwright上调Praxis Precision Medicines股票目标价至1,245美元

Oppenheimer重申Capricor股票"优于大盘"评级，维持54美元目标价

Oppenheimer上调Dianthus Therapeutics股票目标价至125美元，此前为62美元

派博桑德勒将Praxis Precision Medicines股票目标价上调至1,200美元

Roth/MKM 对 Arcturus Therapeutics 股票启动覆盖，给予"买入"评级

野村医疗股票获美银重申"跑赢大盘"评级

Wave Life Sciences股价在Arrowhead数据支持INHBE机制后上涨